Harrow Health, Inc. (HROW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Harrow Health, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Harrow Health, Inc. (HROW) has returned -28.04% so far this year and 32.56% over the past 12 months. Looking at the last ten years, HROW has achieved an annualized return of 24.47%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Sep 28, 2007, HROW's average daily return is +0.35%, while the average monthly return is +2.98%. At this rate, your investment would double in approximately 2.0 years.

Historically, 45% of months were positive and 55% were negative. The best month was Nov 2011 with a return of +214.3%, while the worst month was Jun 2011 at -75.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 11 months.

On a daily basis, HROW closed higher 38% of trading days. The best single day was Mar 16, 2012 with a return of +158.9%, while the worst single day was Mar 19, 2012 at -89.7%.

Harrow Health, Inc. has an annualized alpha of 131.91%, beta of 0.52, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since October 01, 2007.

• This stock participated in 90.35% of S&P 500 Index downside but only 30.03% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.52 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HROW ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Harrow Health, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Harrow Health, Inc. was 99.46%, occurring on Mar 19, 2012. The portfolio has not yet recovered.

The current Harrow Health, Inc. drawdown is 74.45%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Harrow Health, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Harrow Health, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.